JKJan Jacob Koornstra

Jan Jacob Koornstra

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jan Jacob Koornstra has a total of 53 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Vitamin D Status and Colorectal Neoplasm Risk in Lynch Syndrome

    by Marjolein T. Bulbaai, Evertine Wesselink, Monique E. van Leerdam, Tanya M. Bisseling, Jan Jacob Koornstra, Femke Fleur Verstraete, Polly A. Newcomb, Stephanie L. Schmit, N. Jewel Samadder, Michelle Cotterchio, et al.

    Background: Higher circulating vitamin D concentrations have been associated with a decreased colorectal neoplasm (CRN) risk in the general population. However, this association has not yet been investigated in individuals with Lynch syndrome (LS), an inherited predisposition to colorectal cancer. Methods: The study population included 2,351 LS carriers from the GEOLynch and the Colon Cancer Family Registry cohorts. Total plasma 25-hydroxyvitamin D [25(OH)D; 25(OH)D2 and 25(OH)D3] concentrations were measured using isotope dilution LC/MS-MS. CRNs included adenomas, serrated lesions, and colorectal cancer. Multivariable Cox proportional hazards models estimated hazard ratios (HR) and 95% confidence intervals (CI) for the association between 25(OH)D concentrations and CRN risk, overall and by pathogenic variant type, age, sex, CRN history, and geographic region. Results: During a median follow-up of 7.2 years (IQR, 3.3–12.6), 647 (27.5%) LS carriers developed a CRN. No association was observed for deficient (<50 nmol/L or <20 ng/mL; HR, 1.12; 95% CI, 0.91–1.39) or optimal (≥75 nmol/L or ≥30 ng/mL; HR, 0.94; 95% CI, 0.77–1.15) compared with sufficient (50 to <75 nmol/L or 20 to <30 ng/mL) vitamin D concentrations. No association was observed for each 10 nmol/L or 4 ng/mL increment in vitamin D concentration. Among PMS2 carriers, a 10 nmol/L increment was associated with a 27% lower CRN risk (HR, 0.73; 95% CI, 0.58–0.91). Conclusions: Vitamin D concentrations were not associated with CRN risk among LS carriers, whereas the association observed among PMS2 carriers warrants further investigation. Impact: If confirmed, these findings could inform personalized risk reduction strategies for PMS2 carriers.

  • Open Access

    Substantial and sustained improvement of serrated polyp detection after a simple educational intervention: results from a prospective controlled trial

    by Arne G C Bleijenberg, Monique E van Leerdam, Marloes Bargeman, Jan Jacob Koornstra, Yasmijn J van Herwaarden, Manon Cw Spaander, Silvia Sanduleanu, Barbara A J Bastiaansen, Erik J Schoon, Niels van Lelyveld, et al.

    Objective Serrated polyps (SPs) are an important cause of postcolonoscopy colorectal cancers (PCCRCs), which is likely the result of suboptimal SP detection during colonoscopy. We assessed the long-term effect of a simple educational intervention focusing on optimising SP detection. Design An educational intervention, consisting of two 45 min training sessions (held 3 years apart) on serrated polyp detection, was given to endoscopists from 9 Dutch hospitals. Hundred randomly selected and untrained endoscopists from other hospitals were selected as control group. Our primary outcome measure was the proximal SP detection rate (PSPDR) in trained versus untrained endoscopists who participated in our faecal immunochemical test (FIT)-based population screening programme. Results Seventeen trained and 100 untrained endoscopists were included, who performed 11 305 and 51 039 colonoscopies, respectively. At baseline, PSPDR was equal between the groups (9.3% vs 9.3%). After training, the PSPDR of trained endoscopists gradually increased to 15.6% in 2018. This was significantly higher than the PSPDR of untrained endoscopists, which remained stable around 10% (p=0.018). All below-average (ie, PSPDR ≤6%) endoscopists at baseline improved their PSPDR after training session 1, as did 57% of endoscopists with average PSPDR (6%–12%) at baseline. The second training session further improved the PSPDR in 44% of endoscopists with average PSPDR after the first training. Conclusion A simple educational intervention was associated with substantial long-term improvement of PSPDR in a prospective controlled trial within FIT-based population screening. Widespread implementation of such interventions might be an easy way to improve SP detection, which may ultimately result in fewer PCCRCs. Trial registration number NCT03902899.


  • Open Access

    Personalised surveillance for serrated polyposis syndrome: results from a prospective 5-year international cohort study

    by Arne Gc Bleijenberg, Joep Eg Ijspeert, Yasmijn J van Herwaarden, Sabela Carballal, María Pellisé, Gerhard Jung, Tanya M Bisseling, Iris D Nagetaal, Monique E van Leerdam, Niels van Lelyveld, et al.

    Background and aims Serrated polyposis syndrome (SPS) is associated with an increased risk of colorectal cancer (CRC). International guidelines recommend surveillance intervals of 1–2 years. However, yearly surveillance likely leads to overtreatment for many. We prospectively assessed a surveillance protocol aiming to safely reduce the burden of colonoscopies. Methods Between 2013 and 2018, we enrolled SPS patients from nine Dutch and Spanish hospitals. Patients were surveilled using a protocol appointing either a 1-year or 2-year interval after each surveillance colonoscopy, based on polyp burden. Primary endpoint was the 5-year cumulative incidence of CRC and advanced neoplasia (AN) during surveillance. Results We followed 271 SPS patients for a median of 3.6 years. During surveillance, two patients developed CRC (cumulative 5-year incidence 1.3%[95% CI 0% to 3.2%]). The 5-year AN incidence was 44% (95% CI 37% to 52%), and was lower for patients with SPS type III (26%) than for patients diagnosed with type I (53%) or type I and III (59%, pConclusion Risk stratification substantially reduced colonoscopy burden while achieving CRC incidence similar to previous studies. AN incidence is considerable in SPS patients, but extension of surveillance intervals was not associated with increased AN in those identified as low-risk by the protocol. We identified SPS type III patients as low-risk group that might benefit from even less frequent surveillance. Trial registration number The study was registered on http://www.trialregister.nl; trial-ID NTR4609.


  • Open Access

    Extracolonic cancer risk in Dutch patients with APC (adenomatous polyposis coli)-associated polyposis

    by Zeinab Ghorbanoghli, Barbara Aj Bastiaansen, Alexandra Mj Langers, Fokko M Nagengast, Jan-Werner Poley, James Ch Hardwick, Jan J Koornstra, Silvia Sanduleanu, Wouter H de Vos Tot Nederveen Cappel, Ben Jm Witteman, et al.

    Background Screening of patients with familial adenomatous polyposis (FAP) have led to a substantial reduction in mortality due to colorectal cancer (CRC). Recent guidelines suggest that surveillance of non-intestinal malignancies should also be considered in those patients. However, the value of these surveillance programmes is unknown. The aims of this study were (1) to assess the occurrence of extracolonic malignancies in a large series of adenomatous polyposis coli (APC) mutation carriers and (2) to evaluate the causes of death. Methods All APC mutation carriers were selected from the Dutch polyposis registry. Data on causes of death were collected. Pathology reports were retrieved from the Dutch Pathology Registry. Results A total of 85 extracolonic malignancies were diagnosed in 74 of 582 APC mutation carriers. Duodenal and skin cancers were the most prevalent cancers. Thyroid cancer was observed in only 1.5% of the cases. The main cause of death was cancer (59% of all deaths), with 42% due to CRC and 21% due to duodenal cancer. One patient died from thyroid cancer. The second and third most common causes of death were cardiovascular disease (13% of all deaths) and desmoid tumours (11% of all deaths), respectively. Conclusion Extending surveillance programmes to other cancers will not contribute significantly to the survival of patients with FAP.


  • Early Carcinogenic Events in HNPCC Adenomas: Differences with Sporadic Adenomas

    by Fleur Elise Marie Rijcken, Jan Jacob Koornstra, Tineke van der Sluis, Wytske Boersma-Van Ek, Jan H. Kleibeuker, Harry Hollema

    Background Tumorigenesis in hereditary nonpolyposis colorectal cancer (HNPCC) differs from that in sporadic colorectal cancer during the early stage. We examined the expression of proliferation- and apoptosis-regulating proteins in relation to proliferation and apoptosis in HNPCC and sporadic adenomas. Methods Proliferation and apoptosis were quantified, and the expression of cyclin B1, D3 and E, p21, p27, bcl-2, bax, p53 and cox-2 was determined by immunohistochemistry in 100 patients (42 with HNPCC and 48 with sporadic adenomas). Results No differences between the two groups of patients in terms of proliferation and apoptosis were detected. Low-grade dysplastic HNPCC adenomas differed from sporadic ones by expressing bcl-2 more often (69 vs. 42%) and bax less often (50 vs. 73%). In comparison to sporadic adenomas, fewer high-grade dysplastic HNPCC expressed cyclin B1 and E (50 and 38% vs. 87 and 87%, respectively), p21 (6% vs. 53%) and bax (31% vs. 80%). In addition, HNPCC adenomas had a lower overexpression of p53 (5 vs. 19%). Conclusion The expression of cell cycle- and apoptosis-related proteins differs between HNPCC and sporadic adenomas from early through to advanced stages although proliferation and apoptosis are not different. These differences may contribute to the different clinical behavior of HNPCC and sporadic adenomas.